Global Leading Market Research Publisher QYResearch announces the release of its latest report “Pharmacogenomics Services – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. For healthcare providers, pharmaceutical companies, and precision medicine investors, the historic “one-size-fits-all” approach to drug prescribing has long been recognized as a fundamental limitation of modern medicine. Patients with the same diagnosis often respond differently to the same medication—some experience therapeutic benefit, others no effect, and still others adverse reactions—with genetic variation playing a critical role in determining drug efficacy and safety. Pharmacogenomics services address this challenge by analyzing how an individual’s genetic makeup influences their response to medications, enabling healthcare providers to select the right drug at the right dose for each patient. This report delivers a comprehensive strategic assessment of a market poised for steady growth, quantifying the value proposition that is driving adoption across oncology, psychiatry, cardiology, and infectious disease as healthcare systems increasingly embrace personalized approaches to drug therapy.
Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Pharmacogenomics Services market, including market size, share, demand, industry development status, and forecasts for the next few years. The global market for Pharmacogenomics Services was estimated to be worth US$ 1444 million in 2024 and is forecast to a readjusted size of US$ 2062 million by 2031 with a CAGR of 5.3% during the forecast period 2025-2031.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/3670798/pharmacogenomics-services
Market Trajectory: Steady Growth Anchored in Precision Medicine Adoption
The projected 5.3% CAGR reflects a market benefiting from the accelerating adoption of precision medicine across healthcare systems. According to recent data from the Personalized Medicine Coalition and industry analysts, the number of FDA-approved pharmacogenomic biomarkers included in drug labels has increased from fewer than 50 in 2010 to over 300 in 2024, reflecting the growing evidence base linking genetic variation to drug response. Each new biomarker creates opportunities for pharmacogenomics testing services.
Several factors are driving market expansion. The decreasing cost of genetic testing—with whole genome sequencing now available for under US$ 500—has made pharmacogenomic testing more accessible to patients and healthcare systems. The growing emphasis on value-based care has created incentives for interventions that improve treatment outcomes while reducing adverse events and hospitalizations. Additionally, the expansion of oncology targeted therapies—where pharmacogenomic testing is often required before treatment initiation—has driven significant demand for companion diagnostic services.
Technology Segmentation: Genotyping, SNP Identification, and Pharmacogenetic Testing
The market’s segmentation by service type—Genotyping, SNP Identification, Pharmacogenetic Testing, and Others—reveals the range of analytical approaches used to characterize genetic variation affecting drug response.
Pharmacogenetic Testing represents the core service segment, encompassing targeted analysis of specific genes known to affect drug metabolism and response. Common pharmacogenes include CYP2D6, which affects metabolism of antidepressants, antipsychotics, and opioids; CYP2C19, which affects antiplatelet drugs and proton pump inhibitors; and TPMT, which affects thiopurine drugs used in inflammatory bowel disease and leukemia. A case study from a large health system illustrates the clinical impact: implementation of preemptive pharmacogenetic testing for patients initiating antidepressant therapy reduced time to effective treatment by 40% and reduced adverse drug reactions by 30% through avoidance of medications metabolized by non-functional CYP2D6 variants.
Genotyping encompasses broader analysis of genetic variants across the genome, often using microarray technology. Genotyping services may be offered as part of direct-to-consumer testing platforms or as comprehensive pharmacogenomic panels that include multiple pharmacogenes.
SNP Identification (single nucleotide polymorphism) represents the foundational technology for pharmacogenomic analysis, identifying the specific genetic variants that correlate with drug response phenotypes.
Application Landscape: Oncology, Psychiatry, Cardiovascular, and Infectious Diseases
The oncology application segment represents the largest and most established market for pharmacogenomics services. Many targeted cancer therapies—including tyrosine kinase inhibitors, monoclonal antibodies, and immunotherapies—are indicated only for patients with specific genetic markers. The companion diagnostic model, where testing is required before therapy initiation, has created a predictable, recurring demand for oncology pharmacogenomic testing. A case study from a leading cancer center illustrates this value: the center’s molecular tumor board reviews pharmacogenomic data for all patients with advanced solid tumors, matching patients to targeted therapies based on tumor genetics and normal tissue pharmacogenomic markers.
The psychiatry segment represents the fastest-growing application for pharmacogenomics services, driven by the high rate of antidepressant and antipsychotic non-response and the availability of established pharmacogenetic guidelines. The Clinical Pharmacogenetics Implementation Consortium (CPIC) and the FDA have published guidelines for antidepressant and antipsychotic selection based on CYP2D6 and CYP2C19 genotypes. Recent studies have shown that pharmacogenomically-guided antidepressant selection reduces hospitalizations and emergency department visits by 30-40% compared to standard prescribing.
The cardiovascular segment encompasses testing for warfarin dosing, clopidogrel effectiveness, and statin tolerability. CYP2C19 genotyping for clopidogrel (antiplatelet therapy) has become standard of care in many interventional cardiology practices, as patients with reduced-function variants have increased risk of adverse cardiovascular events.
The infectious diseases segment includes testing for HIV drug resistance and hepatitis C treatment response, where viral genetics—rather than patient genetics—drive treatment selection.
Competitive Landscape: Diagnostic Laboratories and Testing Companies
The pharmacogenomics services market features a diverse landscape spanning large reference laboratories, specialized testing companies, and direct-to-consumer platforms.
Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings, and Exact Sciences Corporation represent the large reference laboratory segment, offering pharmacogenomic testing as part of broader diagnostic portfolios.
Illumina, Inc. , QIAGEN N.V. , Thermo Fisher Scientific Inc. , and Abbott Laboratories supply the instruments and reagents that enable pharmacogenomic testing, with service offerings integrated into their broader product lines.
Myriad Genetics, Inc. , Admera Health, LLC, GeneOmbio Technologies Pvt Ltd. , Precipio, OneOme, LLC, DiaCarta, Inc. , and OPKO Health represent the specialized pharmacogenomic testing companies, with focused service offerings and direct relationships with healthcare providers.
F. Hoffmann-La Roche Ltd. maintains a strong position in companion diagnostics for oncology therapies. 23andMe, Inc. and OmeCare represent the direct-to-consumer segment, offering pharmacogenomic reports directly to consumers, often in combination with ancestry and health risk information.
Exclusive Industry Insight: The Integration Imperative
The defining trend shaping the pharmacogenomics services market is the integration of genetic testing into routine clinical practice. Early pharmacogenomic services operated as standalone testing, requiring separate ordering, specimen collection, and result reporting. The future of the market lies in integration: embedding pharmacogenomic data into electronic health records, providing clinical decision support at the point of prescribing, and enabling preemptive testing that makes pharmacogenomic data available before it is needed.
For strategic decision-makers, the pharmacogenomics services market presents a compelling opportunity characterized by steady growth, expanding clinical evidence, and the integration of genetic testing into standard healthcare delivery. The projected expansion from US$ 1.44 billion to US$ 2.06 billion by 2031 reflects a market where clinical utility, reimbursement, and integration with healthcare IT systems will define competitive success.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
